جستجوی استاد راهنمای دانشگاهی

Weiqiang Chenمشاهده پروفایل

استاد

• Lab-on-a-Chip
• Organ-on-Chip
• Biomaterials
• +۷ مورد دیگر

Weiqiang Chen is a Professor of Mechanical and Biomedical Engineering at New York University's Tandon School of Engineering and Director of Research and PhD Programs. He holds a joint appointment at NYU Langone's Perlmutter Cancer Center as a Faculty Member of the Tumor Immunology Research Program. B.S. in Physics (Nanjing University, 2005) M.S. in Electrical Engineering (Shanghai Jiao Tong University, 2008) M.S. in Electrical and Computer Engineering (Purdue University, 2009) Ph.D. in Mechanical Engineering (University of Michigan, 2014) His research focuses on Lab-on-a-Chip , Organ-on-Chip systems, Biomaterials , and Mechanobiology , with applications in cancer biology, stem cell engineering, and immune monitoring. He pioneers microfabrication technologies for real-time observation of cellular interactions, including CAR T-cell immunotherapy efficacy and tumor microenvironment dynamics. Recent grants include NSF funding for leukemia bone marrow niche modeling, NIH Trailblazer Awards for glioblastoma immunotherapy research, and collaborations with the Arthritis Foundation for synovium-on-chip rheumatoid arthritis studies. His work has been supported by over $2M in federal and institutional research funding. National Science Foundation (NSF) grants for leukemia-on-chip and glioblastoma modeling National Institutes of Health (NIH) awards for immunotherapy research American Heart Association fellowships and institutional training programs Chen's scientific awards include the American Heart Association Fellow distinction, multiple Young Investigator Awards from Lab on a Chip and Biomedical Engineering Society, and recognition for his dissertation on nanotopography in stem cell differentiation. He leads the Applied Micro-Bioengineering Laboratory (AMBL) , which develops microphysiological systems for drug testing and personalized medicine. His team has created the first immunocompetent leukemia-on-a-chip for CAR T-cell therapy screening and glioblastoma models that enable patient-specific immunotherapy validation.

Ashli Owen-Smithمشاهده پروفایل

پژوهشگر

• Mental Health
• Behavioral Science
• Trauma
• +۶ مورد دیگر

Ashli Owen-Smith is a behavioral scientist affiliated with the School of Public Health at Georgia State University , where her research focuses on mental health disparities, suicide prevention, and integrative/complementary approaches for complex mental-physical health conditions. She works with underserved populations including refugees/immigrants, incarcerated individuals, and LGBTQ+ communities through community-based participatory research and mixed-methods frameworks. Her current projects are funded by CDC , DBHDD , and DPH . Education: Ph.D. in Behavioral Sciences (Emory, 2009), S.M. in Public Health (Harvard, 2005), B.A. in Psychology (Smith College, 2001) Her research spans mental health , trauma , suicide prevention , and mindfulness-based interventions . Recent work examines telehealth adaptations for chronic pain and mental health, vaccine hesitancy in refugee communities, and social determinants of suicide . She leads studies on gender-affirming care and health disparities in LGBTQ+ populations. Key article trends include epidemiological analysis of suicide risk factors, COVID-19 impacts on mental health, ICD-10 coding for autism, and complementary medicine in trauma recovery. Subfields span telehealth , health equity , mental-physical comorbidity , and community engagement . Students she has mentored include C.A. Scarlett , T. Griner , and M.M. Sesay . Her work integrates public health policy , clinical research , and health systems analysis .

Canan Dagdevirenمشاهده پروفایل

دانشیار

• Biomedical Engineering
• Piezoelectric Devices
• Wearable Electronics
• +۶ مورد دیگر

Dr. Canan Dagdeviren is an Associate Professor and LG Career Development Professor of Media Arts and Sciences at the Massachusetts Institute of Technology, where she directs the Conformable Decoders research group at the MIT Media Lab. She joined the MIT faculty in January 2017 and has established herself as a leading innovator in conformable biomedical devices. Education: Ph.D. in Materials Science and Engineering, University of Illinois at Urbana-Champaign M.Sc. in Materials Science and Engineering, Sabanci University, Istanbul, Turkey B.Sc. in Physics Engineering, Hacettepe University, Ankara, Turkey Dr. Dagdeviren's research focuses on creating mechanically adaptive electromechanical systems that can intimately integrate with biological surfaces for sensing, actuation, and energy harvesting. She believes vital information from nature and the human body is 'coded' in various physical patterns, and her work develops 'conformable decoders' to translate these patterns into beneficial signals and energy. Her research spans wearable and implantable medical devices, with particular emphasis on piezoelectric systems that can be twisted, folded, stretched, wrapped, and implanted onto curvilinear surfaces of the human body without damage or significant alteration in performance. Analysis of her recent publications reveals a strong focus on medical applications of conformable electronics, particularly in ultrasound technology for breast cancer detection, deep brain stimulation, and bladder monitoring. Her work consistently bridges materials science, electrical engineering, and medical applications, with increasing emphasis on practical healthcare solutions that can be deployed outside clinical settings. Major Scientific Awards: NSF CAREER Award (2021) 3M Non-Tenured Faculty Award (2021) MIT Technology Review's Top 35 Innovators Under 35 (2015) Forbes' Top 30 Under 30 in Science (2015) National Academy of Engineering US Frontiers of Engineering Symposium participant (2019) Frank E. Perkins Award for Excellence in Graduate Advising Aziz Sancar Science Award Dr. Dagdeviren actively mentors graduate students and has received recognition for her advising excellence. Her research is supported by significant grants including the NSF CAREER award and has resulted in numerous patents and commercialization opportunities. She has developed innovative cleanroom-based courses at MIT that train students in microfabrication techniques for biomedical devices. The Conformable Decoders research group operates a specialized cleanroom facility at the MIT Media Lab, enabling the development and fabrication of novel conformable electronic systems. The group's work has attracted attention from major media outlets including BBC, CNN, and Nature, and has potential applications across multiple medical specialties including neurology, oncology, and urology.

Jennifer L Clarkeمشاهده پروفایل

استاد

• Statistical Methodology
• Bioinformatics/Computational Biology
• Data Mining/Machine Learning
• +۳ مورد دیگر

Jennifer L. Clarke is a Professor in the Department of Statistics at the University of Nebraska–Lincoln and Director of the Quantitative Life Science Initiative. She holds leadership roles in enabling big data integration across the University of Nebraska system through collaborative research programs. Her affiliations include the Institute of Agriculture and Natural Resources (IANR) and the College of Agriculture and Natural Resources. Dr. Clarke's research focuses on statistical methodology for high-dimensional data, computational biology, bioinformatics, and bacterial genomics. Her work bridges statistical innovation with applications in oncology, microbiome analysis, and agricultural phenomics. Key areas include predictive modeling, machine learning, and genomic/metagenomic data integration. Her recent publications span cancer biomarker discovery, plant phenotyping methodologies, and microbial community analysis, reflecting her interdisciplinary approach. Articles emphasize translational applications like therapeutic target identification and precision agriculture. Dr. Clarke leads initiatives fostering collaboration between statisticians and domain scientists, including the Quantitative Life Science Initiative and contributions to the Agricultural Genome-to-Phenome Initiative (AG2PI). Her work advances data-driven solutions for healthcare and food security challenges. Notable projects include developing statistical tools for microbiome studies, analyzing root architecture via 3D imaging, and investigating cranberry-derived compounds' cancer-inhibitory mechanisms. Her methodological contributions include hybrid clustering techniques and predictive model validation frameworks.

• Nuclear Magnetic Resonance (NMR)
• In vivo imaging
• MRI pulse sequence development
• +۷ مورد دیگر

Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.

John A. Copland, IIIمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +۳ مورد دیگر

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

Ruth Etzioniمشاهده پروفایل

استاد مدعو

• Cancer Screening
• Prostate Cancer Research
• Biomarkers
• +۵ مورد دیگر

Ruth Etzioni is an Affiliate Professor in the Biostatistics Program and Public Health Sciences Division at the Fred Hutchinson Cancer Center. She leads the Etzioni Lab, focusing on cancer screening, early detection, and overdiagnosis analysis. Her work integrates statistical modeling, epidemiology, and clinical research to address critical questions in prostate and breast cancer control. Dr. Etzioni holds the Rosalie & Harold Rea Brown Endowed Chair and has received a $7.4M NIH Outstanding Investigator Award. Education: PhD in Statistics (Carnegie Mellon University, 1990), MS in Statistics (Carnegie Mellon, 1987), BS in Mathematics (University of Cape Town, South Africa). Research interests emphasize biomarkers, clinical trials, and epidemiological methods. She leads the Biostatistics Core for the Pacific Northwest Prostate Cancer SPORE and participates in the Cancer Intervention and Surveillance Modeling Network (CISNET). Her lab develops models to evaluate screening policies, quantify overdiagnosis, and inform healthcare disparities reduction strategies. Key achievements include groundbreaking work on prostate cancer screening's harm-benefit tradeoffs and contributions to multi-cancer early detection (MCED) frameworks. Recent studies address racial disparities in prostate cancer outcomes, metastasis trends, and the clinical utility of novel diagnostics like PSMA PET imaging. Awards include the Brown Endowed Chair (2020), NCI OIA Award (2023), and recognition for advancing cancer data science. Her lab collaborates with institutions globally and mentors students in biostatistics and translational data science.

Benjamin Andrew Tollمشاهده پروفایل

استاد

• Tobacco Cessation
• Smoking Cessation
• Cancer Prevention
• +۵ مورد دیگر

Benjamin Andrew Toll is a Professor in the Department of Public Health Sciences and Psychiatry at the Medical University of South Carolina (MUSC) College of Medicine. He serves as Associate Director of Education and Training for the Hollings Cancer Center, Vice Chair of Research in the Department of Public Health Sciences, Co-Director of the Lung Cancer Screening Program, and Director of the Tobacco Treatment Program at MUSC. Dr. Toll received his BA from Cornell University (1996), MS and PhD from Nova Southeastern University (1999, 2002), and completed his Postdoctoral Fellowship and Internship at Yale University. Dr. Toll is a leading researcher in tobacco cessation, with over 20 years of experience conducting clinical trials focused on developing novel therapeutics for tobacco and nicotine use. His work primarily centers on preventing cancer through tobacco treatment interventions, with particular emphasis on lung cancer screening patients and cancer surgery patients. He has expertise in nicotine replacement therapy, contingency management approaches, gain-framed messaging, and digital health interventions for smoking cessation across diverse populations including older adults and young adults. His recent publications demonstrate a strong focus on implementation science for tobacco treatment programs across various healthcare settings including hospitals, oncology clinics, and primary care. His research examines barriers to treatment, optimal delivery methods (including telehealth and EHR-integrated tools), and effectiveness of various pharmacological and behavioral interventions for smoking cessation. National Cancer Institute funding (R01CA235697, R01CA207229, P50CA196530) National Institute on Drug Abuse funding (P50DA036151, K12DA000167) Continuous funding for over 15 years for tobacco cessation research As a mentor and leader, Dr. Toll oversees the Education and Training program at the Hollings Cancer Center, guiding the development of future cancer researchers. His Tobacco Treatment Program serves as a model for integrating tobacco cessation into comprehensive cancer care, and he has successfully implemented 'opt-out' tobacco treatment programs across multiple hospital systems in South Carolina. Dr. Toll leads a multidisciplinary research team focused on tobacco treatment, including psychologists, pharmacists, physicians, and implementation scientists working together to develop and test innovative approaches to smoking cessation for high-risk populations.

Abbas Samaniمشاهده پروفایل

استاد

• Biomedical Engineering
• Medical Imaging
• Computational Modeling
• +۵ مورد دیگر

Prof. Abbas Samani is a Professor at the Department of Electrical and Computer Engineering and holds a joint appointment in the Department of Medical Biophysics at Western University . He is a core faculty member of the Biomedical Engineering Graduate Program and an Associate Scientist at Imaging Research Laboratories of Robarts Research Institute . His academic journey includes a Ph.D. from the University of Waterloo, an M.Sc. from the University of Tehran, and a B.Sc. from Amirkabir University of Technology. His research focuses on biological tissue computational modeling and its applications in medical imaging, intervention, and image analysis . He develops computer/image-assisted tools for minimally invasive disease diagnosis and therapy , targeting heart disease, cancer, and lung disease . Key projects include myocardium biomechanical modeling , handheld medical devices for breast cancer screening , and lung disease diagnostics via CT image segmentation . His recent publications emphasize ultrasound elastography , finite element modeling , and inverse problems in biomechanics , primarily in journals like IEEE Transactions on Computational Imaging and Translational Oncology . His work spans both computational modeling and medical device development . Selected Graduate Supervision : Ph.D. Candidates : Seyed Hassan Haddad, Elham Karami, Seyed Mohammad Hesabgar Graduated Ph.D. Students : Ali Sadeghi Naini, Seyed Reza Mousavi M.Sc. Students : Cristian Linte, Patrick Courtis, Joseph O'Hagan, Hatef Mehrabian, Hirad Karimi, Hosein Amooshahi, Seyed Mohammad Hesabgar, Nastaran Ghadarghadr, Shadi Shavakh, Ehsan Salamati, Ehsan Omidi Teaching Contributions : Graduate: BME9519B/CAMI9519B/ECE9202B/ECE9022B - Advanced Image Processing and Analysis , MBP9530A - Human Biomechanics and Biomedical Applications Undergraduate: ECE4438B - Advanced Image Processing and Analysis , ES1050 - Introductory Engineering Design and Innovation Studio , MBP3330F - Human Biomechanics and Biomedical Applications Research Affiliations : Robarts Research Institute - Associate Scientist at Imaging Research Laboratories Western University - Core Faculty, Biomedical Engineering Graduate Program

Raphael Franziniمشاهده پروفایل

دانشیار

• Drug Discovery
• Medicinal Chemistry
• Bioorthogonal Chemistry
• +۳ مورد دیگر

Raphael Franzini serves as Associate Professor of Medicinal Chemistry at the University of Utah, actively contributing to the Biological Chemistry PhD Program. His research pioneers innovative chemical approaches for therapeutic development, with dual focus on DNA-encoded library technologies and bioorthogonal drug delivery systems. His educational foundation includes an M.S. from the Swiss Federal Institute of Technology (Lausanne) and a Ph.D. from Stanford University. This training underpins his group's multidisciplinary methodology combining organic synthesis, bioconjugation, computational modeling, and advanced imaging techniques. Dr. Franzini's research program centers on two transformative areas: First, advancing DNA-encoded library screening through computational integration to identify leads for challenging targets like Tankyrase and Sirtuin 6, with recent work addressing false negatives in machine learning prediction. Second, developing novel bioorthogonal release chemistry using isonitrile-tetrazine reactions for spatiotemporally controlled drug activation, validated in zebrafish models. His group emphasizes both technological innovation and therapeutic translation, with chemistry designed to minimize off-target effects in solid tumors. Analysis of his 15 most recent publications reveals escalating integration of computational methods with experimental library screening, alongside refinement of bioorthogonal release kinetics. The work spans chemical biology, medicinal chemistry, and pharmaceutical sciences, with growing emphasis on machine learning for library data interpretation and in vivo validation of drug-release systems. Dr. Franzini maintains an active research laboratory that provides comprehensive training in cutting-edge drug discovery methodologies. His group culture prioritizes both scientific innovation and researcher development, with projects spanning from fundamental reaction kinetics to therapeutic applications. The lab's infrastructure supports organic synthesis, molecular imaging, and computational analysis for advancing precision therapeutics.

Rong Fanمشاهده پروفایل

استاد

• Single-cell Omics
• Spatial Omics
• Immunology
• +۵ مورد دیگر

Dr. Rong Fan is the Harold Hodgkinson Professor of Biomedical Engineering and Professor of Pathology at Yale University. His research focuses on developing and applying single-cell and spatial omics technologies to study immune systems, cancer, and aging. His lab has pioneered technologies like the IsoCode microchip for high-throughput protein profiling, and spatial multi-omics platforms (e.g., DBiT-seq, spatial-ATAC-seq) to analyze tissue complexity at cellular resolution. He co-founded IsoPlexis, Singleron Biotechnologies, and AtlasXomics to commercialize these innovations. Education: PhD in Chemistry from UC Berkeley (2006), B.S. in Applied Chemistry from University of Science and Technology of China (1999). Postdoctoral training at Caltech before joining Yale in 2010. Research interests include CAR-T cell therapy optimization, spatial epigenomics, and multi-omics integration. Key achievements include discovering biomarkers predictive of CAR-T efficacy and defining spatial genomic landscapes in cancer and neuroinflammation. Awards: NSF CAREER Award, Packard Fellowship, election to AIMBE, CASE, and NAI. Serves on advisory boards for Bio-Techne and Yale Ventures. Active in training future scientists via the Yale Biomedical Engineering and Yale School of Medicine programs.

Brent Pageمشاهده پروفایل

دانشیار

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +۱۳ مورد دیگر

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

Guy Davidمشاهده پروفایل

استاد

• Health Economics
• Industrial Organization
• Applied Microeconomics
• +۵ مورد دیگر

Guy David is the Alan B. Miller Professor of Health Care Management at the Wharton School and Professor of Medical Ethics and Health Policy at the Perelman School of Medicine, University of Pennsylvania. He chairs the Health Care Management Department and serves as a Research Associate at the National Bureau of Economic Research and Senior Fellow at the Leonard Davis Institute of Health Economics. Education: PhD in Business Economics, University of Chicago (2004) MA in Economics, Tel-Aviv University (1997) BA in Economics, Tel-Aviv University (1995) Research Interests: Applied microeconomics in healthcare markets Industrial organization and regulation of post-acute care Dynamics of mixed-ownership competition in healthcare Patient-centered medical care and welfare effects Emergency medical services economics Direct-to-consumer advertising and drug safety Division of labor in care continuum Publication Trends: His research focuses on antitrust implications in nonprofit hospitals, schedule volatility in healthcare workforce, performance pay incentives in Medicare, and pandemic-related healthcare disruptions. Recent work examines telemedicine adoption, preventive care disruptions, and provider-patient engagement length in home health care. Scientific Awards: National Bureau of Economic Research Dissertation Fellowship (2003-04) University of Pennsylvania Research Foundation Awards (2006, 2009) Leonard Davis Institute Pilot Project Awards (2007, 2009) NIH Grant (2008) Multiple Wharton Teaching Excellence Awards (2014, 2017, 2018) Leadership & Grants: He leads the Wharton-Anthem Research Initiative, co-edits the International Journal of Health Economics and Management , and was former director of the Health Care Management and Economics PhD program. His work has been funded by NIH, NBER, Leonard Davis Institute, and University of Pennsylvania.

• Medical Image Analysis
• Machine Learning in Medical Imaging
• Neuroimaging
• +۵ مورد دیگر

Lawrence Staib is Professor of Radiology and Biomedical Imaging, Biomedical Engineering, and Electrical Engineering at Yale University. He serves as Director of Undergraduate Studies in Biomedical Engineering and is a member of Yale's Bioimaging Sciences division, Image Processing & Analysis Group, Yale Biomedical Imaging Institute, and Yale-BI Biomedical Data Science Fellowship program. Dr. Staib earned his A.B. in Physics from Cornell University (1982), followed by a Ph.D. in Engineering and Applied Science from Yale University (1990), and completed a postdoctoral fellowship at Yale School of Medicine (1991). His research focuses on developing advanced medical image analysis methods using machine learning and model-based approaches. Key research areas include neuroimaging applications for autism spectrum disorder classification, cardiac imaging analysis for strain and motion assessment, prostate cancer diagnosis and risk mapping, and innovative techniques for medical image segmentation with limited labeled data. Dr. Staib's work emphasizes uncertainty estimation in deep learning models, multi-modal image registration, and domain adaptation techniques to improve clinical decision support systems. His recent publications demonstrate a strong trend toward developing interpretable AI models for clinical applications, with particular emphasis on fMRI analysis for neurological conditions, cardiac motion analysis, and prostate cancer diagnosis. His work frequently addresses the challenge of limited labeled data in medical imaging through innovative self-supervised, semi-supervised, and few-shot learning approaches. Fellow of the American Institute for Medical and Biological Engineering (AIMBE) (2015) Distinguished Investigator Award from the Academy for Radiology & Biomedical Imaging Research (2017) MICCAI Fellow (2022) Medical Image Analysis Second Best MICCAI Paper Award (2005) ASNR Cum Laude Scientific Exhibit Award (2003) Dr. Staib serves on the editorial board of Medical Image Analysis and as Associate Editor of IEEE Transactions on Biomedical Engineering. His research is supported by NIH grants including the Autism Center of Excellence program. He leads the Image Processing & Analysis Group within Yale's Bioimaging Sciences division, collaborating extensively with James Duncan, John Onofrey, Xenophon Papademetris, and other Yale researchers on applications spanning neuroimaging, cardiology, and oncology. Current projects focus on developing robust AI models for clinical decision support with emphasis on uncertainty quantification and interpretability.

Theresa Raimondoمشاهده پروفایل

استادیار

• Biomaterials
• Drug Delivery
• RNA-based Therapeutics
• +۵ مورد دیگر

Theresa Raimondo is the Manning Assistant Professor of Engineering at Brown University, with a secondary appointment in the Division of Biology and Medicine. She joined the Brown Engineering faculty in January 2024 after completing her postdoctoral training at MIT's Koch Institute. Dr. Raimondo leads the Raimondo Research Lab, which focuses on chemically modifying RNA and designing nanoparticles for therapeutic delivery to the body, an immunotherapy concept that holds immense promise in the field of immunoengineering. Her educational background includes: PhD in Engineering Sciences – Bioengineering from Harvard University (2019) MEng from Harvard University (2019) Sc.B. in Chemical and Biochemical Engineering from Brown University (2011) Dr. Raimondo's research is broadly focused on the design of targeted drug-delivery vectors and novel RNA-based therapeutics for applications in cancer, immunotherapy, and tissue regeneration. Her work primarily centers on developing novel lipid nanoparticles (LNPs) for RNA-based therapies, contributing to adjuvanted mRNA-based vaccines and siRNA-based cancer immunotherapies. By optimizing LNP formulation and modulating RNA constructs, she seeks to understand how RNA-LNPs modulate immunity and develop new therapeutic approaches. Her expertise spans biomaterials, drug delivery, biomolecular engineering, nanomedicine, tissue engineering, and regenerative medicine. Analysis of Dr. Raimondo's recent publications reveals a strong focus on RNA delivery systems and lipid nanoparticle technology. Her work spans from fundamental studies on nanoparticle design to applications in cancer immunotherapy, vaccine development, and tissue regeneration. A significant portion of her research involves optimizing lipid formulations for improved mRNA delivery and exploring how these systems interact with the immune system. Her publications demonstrate a trajectory from basic biomaterials research to increasingly translational work with therapeutic applications. Dr. Raimondo has received numerous prestigious awards: 2025 NAE Symposium selection (Grainger Foundation Frontiers of Engineering) 2025 appointment to the inaugural Early Career Board of ACS Applied Bio Materials 2024 selection as MIT Faculty Founder Initiative finalist 2022 Convergence Scholar fellowship from MIT's Marble Center for Cancer Nanomedicine National Science Foundation graduate research fellowship Harvard's Smith family graduate fellowship Dr. Raimondo is actively involved in mentoring students through courses including ENGN 0931L - Biomedical Engineering Design and Innovation II, ENGN 1490 - Biomaterials, and ENGN 1931L - Biomedical Engineering Design and Innovation II. Her research program is supported by various grants, though specific funding sources aren't detailed in the provided text. The Raimondo Research Lab represents a dynamic environment where engineering principles are applied to solve complex biological challenges in drug delivery and regenerative medicine. The Raimondo Research Lab at Brown University serves as a hub for innovation in RNA delivery and biomaterials design. The lab brings together expertise in chemical engineering, molecular biology, and immunology to develop next-generation therapeutic platforms. Current research directions include optimizing lipid nanoparticle formulations, exploring novel RNA modifications, and investigating immune responses to RNA therapeutics across various disease contexts.